Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

Research output: Contribution to journalArticle


Because new modes of action for the treatment of psoriatic arthritis (PsA) are emerging, it is important to understand the use of switching to a second or third antitumor necrosis factor (anti-TNF) agent. This study investigated drug survival and treatment response rates of patients with PsA undergoing second- and third-line anti-TNF therapy.


  • Lars Erik Kristensen
  • Elisabeth Lie
  • Lennart Jacobsson
  • Robin Christensen
  • Philip J Mease
  • Henning Bliddal
  • Pierre Geborek
External organisations
  • Skåne University Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Rheumatology and Autoimmunity
Original languageEnglish
Pages (from-to)81-87
JournalJournal of Rheumatology
Issue number1
Publication statusPublished - 2016
Publication categoryResearch
Externally publishedYes